Marina Biotech, Inc. Announces That Licensee ProNAi Therapeutics, Inc. Reported Phase 1 Study Results Using SMARTICLES® Nucleic Acid Delivery Technology
12/5/2012 9:42:39 AM
More...
|
ProNAi Therapeutics, Inc. Expands Management Team and Presents Encouraging Phase I Study Results for Lead Cancer Drug at Cancer Meeting
11/12/2012 8:52:08 AM
More...
|
Marina Biotech, Inc. (Formerly Known as MDRNA, Inc.) and ProNAi Therapeutics, Inc. Announce License Agreement for Up to $14 Million
3/14/2012 6:52:23 AM
More...
|
ProNAi Therapeutics, Inc. Cleared to Begin Phase I Clinical Trials for the First DNA Interference (DNAi(R)) Therapeutic
3/20/2008 6:20:13 AM
More...
|
ProNAi Therapeutics, Inc. Announces First DNAi(R) Mechanism of Action Studies for PNT2258 Oncology Drug Candidate
8/23/2007 9:07:05 AM
More...
|
ProNAi Therapeutics, Inc. Names Polymun Scientific Immunbiologische Forschung GmbH as Preferred Manufacturer of PNT2258 DNAi(R)-based Cancer Therapeutic
6/14/2007 12:57:03 PM
More...
|
ProNAi Therapeutics, Inc. Announces Preclinical Success for PNT2258 Therapeutic - Curative Events in Xenograft Mice for Difficult-to-Treat Non-Hodgkin's Lymphoma
4/17/2007 1:04:50 PM
More...
|
ProNAi Therapeutics, Inc. and Novosom Announce Collaboration to Enable Delivery of DNAi(R)-Based Cancer Therapeutics
3/6/2007 1:12:57 PM
More...
|
ProNAi Therapeutics, Inc. Closes Successful Bridge Funding Round, Secures $6.65 Million Total
10/24/2006 9:50:10 AM
More...
|
ProNAi Therapeutics, Inc. Announces New Scientific Advisory Board
10/12/2006 10:54:10 AM
More...
|
|